Activating FGFR3-mutations targetable by FGFR-TKIs have been initially described in subsets of urogenital cancers, but more recently oncogenic mutations affecting the extracellular and transmembrane domains of FGFR3 have also been identified in a minority of pulmonary SqCCs [185,186,187]. Here, FGFR3 is linked to urogenital neoplasm.